)
Edge6 Feb 2026
SharkNinja: Viral by Design
How SharkNinja built a repeatable growth engine, turning overlooked appliance categories into global brands through consumer insight and iteration.
ProMIS Neurosciences
ProMIS Neurosciences (PMN) investor relations material
ProMIS Neurosciences Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary11 Feb, 2026
Key milestones and financial position
Completed enrollment of 144 patients in a robust, oversubscribed phase 1b Alzheimer's study in December, with full financing secured through upcoming data readouts.
Raised up to $175 million in an oversubscribed financing round led by top-tier investors, ensuring funding through key clinical milestones.
Interim analysis of trial data is expected mid-year, with final top-line results anticipated by year-end.
The study design features monthly dosing over 12 months, dose escalation, and placebo control for early Alzheimer's patients.
High patient retention and investigator enthusiasm have resulted in over-enrollment and strong trial execution.
Scientific platform and differentiation
Proprietary EpiSelect platform enables design of highly selective antibodies targeting toxic oligomers, believed to drive neurodegeneration.
PMN310 is the only antibody in development shown not to bind plaque or monomers, focusing exclusively on toxic oligomers.
Preclinical studies demonstrate strong efficacy and safety, with no plaque binding and reduced risk of ARIA compared to other therapies.
The platform supports a pipeline targeting ALS, Parkinson's, and Lewy body dementia, with proof of concept in Alzheimer's expected to validate broader applications.
The approach is now gaining industry acceptance, with other companies shifting focus to oligomers, but PMN310 remains uniquely selective.
Clinical trial design and endpoints
The Precise AD trial is a 12-month, placebo-controlled, double-blind, randomized phase 1b study with three ascending doses (5, 10, 20mg/kg).
Enrolled patients have early Alzheimer's (MCI due to AD), with a homogeneous population screened for disease presence.
Endpoints include a comprehensive biomarker panel, safety (especially ARIA), and clinical outcomes using FDA-approved measures (CDR sum of boxes, ADAS-Cog).
The study is powered to detect ARIA, with front-loaded MRIs to capture early events; over 90% of ARIA cases in similar studies occur within six months.
No treatment-related serious adverse events or ARIA have been observed to date, and dropout rates are significantly lower than industry norms.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next ProMIS Neurosciences earnings date
Q4 202530 Mar, 2026
ProMIS Neurosciences
Next ProMIS Neurosciences earnings date
Q4 202530 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
ProMIS Neurosciences Inc is a Canada-based biotechnology company focused on the discovery and development of antibody therapeutics for neurodegenerative diseases. The company uses a proprietary computational platform to design monoclonal antibodies that selectively target toxic misfolded proteins implicated in conditions such as Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and Parkinson's disease. ProMIS conducts preclinical and early-stage clinical development in collaboration with academic and industry partners. The company is headquartered in Toronto, Ontario, and its shares are listed on the TSX.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage